regenerative medicine

Relativity Acquisition Corp. shareholders approved merger with stem cell firm Instinct Bio Technical Company Inc. Combined entity to trade on Nasdaq as $BIOT and $BIOTW.

Relativity Acquisition shareholders approve SPAC merger with stem cell company Instinct Bio Technical, enabling Nasdaq listing under $BIOT and $BIOTW expected within weeks.

Avaí Bio achieves critical Master Cell Bank milestone for α-Klotho protein therapy, partnering with Austrianova as cell therapy market surges toward $45B by 2035.

Avaí Bio begins manufacturing genetically modified cells overexpressing α-Klotho protein, an anti-aging compound that naturally declines 50% after age 40, advancing its Cell-in-a-Box platform.

CollPlant Biotechnologies launches redesigned website showcasing plant-derived collagen technology, product pipeline, and investor resources to enhance market transparency and stakeholder engagement.

Global orthobiologics market projected to grow 43% to $9.52B by 2031, driven by rising osteoarthritis and regenerative therapy advancements.

BioRestorative Therapies will exhibit at Be+Well Beauty and Wellness Show in NYC (March 8-10, 2026) to advance its BioCosmeceutical platform commercialization.

Cell therapy companies achieve major manufacturing and clinical milestones, positioning sector for explosive growth as global market targets $8.2 billion by 2026.

Cord blood banking market expected to grow 47% to $49.85B by 2031, driven by expanding stem cell therapies and regenerative medicine applications.

BioStem Technologies will present its perinatal tissue-based wound care platform at the TD Cowen Healthcare Conference on March 2, 2026, in Boston.

BioRestorative raised $5M through equity offering to advance stem cell therapies, including BRTX-100 for spine disease and metabolic disorder research.